---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-249373"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2022-09-23T23:59:59+00:00"
generated_at: "2026-06-23T07:48:51.371592+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biomea Fusion EASD data: BMF-219 increases beta cell mass in human islets, improves glycemic control in rat T2D models

## Summary
- BMF-219 increased beta cell mass in ex vivo human donor islets, first such translational data presented.
- In ZDF rats, OGTT AUC reduced 54% vs vehicle (p<0.001) during treatment; 40% reduction maintained 2 weeks after washout (p<0.05).
- In STZ rats, BMF-219 nearly doubled HOMA-B (+96%) and restored non-fasting glucose to near-normal by day 8.
- BMF-219 reduced blood lipemic levels and body weight in both ZDF and STZ rat models.
- Company remains on track to file IND for BMF-219 in type 2 diabetes in second half of 2022.

## SEC filing metadata
- accession: 0001193125-22-249373
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2022-09-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000119312522249373/0001193125-22-249373-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000119312522249373/d397871d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-249373
- JSON: https://secwatch.observer/filing/0001193125-22-249373.json
- Plain text: https://secwatch.observer/filing/0001193125-22-249373.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.